Non-Hodgkin's Lymphoma
GO44145
A Phase III, Multicenter, Randomized, Open‑Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination with Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (POLA-R-CHP) Versus POLA‑R‑CHP in Previously Untreated Patients with Large B-Cell Lymphoma
M22-003
Study of Subcutaneous Epcoritamab in Combination with Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants with Previously Untreated Follicular Lymphoma (EPCORE™FL-2)
S2308
RANDOMIZED PHASE III STUDY OF MOSUNETUZUMAB VS. RITUXIMAB FOR LOW TUMOR BURDEN FOLLICULAR LYMPHOMA
